A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Hutchmed
Eli Lilly and Company
Exelixis
Incyte Corporation
Alaunos Therapeutics
Jazz Pharmaceuticals
Istari Oncology, Inc.
BioMimetix JV, LLC
Regeneron Pharmaceuticals
Servier
Amgen
Basilea Pharmaceutica
Celgene
Istari Oncology, Inc.
Candel Therapeutics, Inc.
Lumos Pharma
Exelixis
Novartis
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Istari Oncology, Inc.
Eisai Inc.
Novartis
TVAX Biomedical
TVAX Biomedical
Bristol-Myers Squibb
Karyopharm Therapeutics Inc
Medicenna Therapeutics, Inc.
Eisai Inc.
Boston Scientific Corporation
Celgene
Five Prime Therapeutics, Inc.
Celgene
Hoffmann-La Roche
Pfizer
Boehringer Ingelheim
Diffusion Pharmaceuticals Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
MedImmune LLC
Novartis
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Isarna Therapeutics GmbH
GE Healthcare
INSYS Therapeutics Inc
GlaxoSmithKline
Pfizer
Novartis